Corvus Pharmaceuticals(CRVS) - 2025 Q1 - Earnings Call Presentation

Soquelitinib Atopic Dermatitis Phase 1 Data - A Phase 1 clinical trial of Soquelitinib in Atopic Dermatitis (AD) demonstrated activity through a novel mechanism of action[7] - The study included 64 participants with moderate to severe AD, randomized into different Soquelitinib dosage cohorts (100 mg BID, 200 mg QD, 200 mg BID, 400 mg QD) and placebo groups[9] - In Cohorts 1 and 2, the Soquelitinib group (N=24) showed a 54.6% mean reduction in EASI score at 4 weeks, compared to a 30.6% reduction in the placebo group (N=8)[15] - In Cohort 3, the Soquelitinib group (N=8) achieved a 71.1% mean reduction in EASI score at 4 weeks, while the placebo group (N=4) had a 42.1% reduction[15] - At day 28, 63% of patients in Soquelitinib Cohort 3 achieved EASI 75, and 25% achieved IGA 0 or 1, compared to 0% in the placebo group[21] - Across Cohorts 1, 2, and 3, 33.3% of Soquelitinib-treated subjects (N=36) experienced Adverse Events (AEs), compared to 25% in the placebo group (N=12)[22] Business Update and Protocol Amendment - A protocol amendment replaces Cohort 4 with an extension cohort to optimize Phase 2 plans, increasing the treatment duration to 8 weeks for 24 patients randomized 1:1 to Soquelitinib 200 mg BID or placebo[24, 25, 26] - The extension cohort will evaluate a longer 56-day treatment duration[27]